SEC Comment Letter for Addex Therapeutics Ltd. (ADXN) (CIK 0001574232) (ADXN) — May 9, 2023
Addex Therapeutics Ltd. (ADXN) (CIK 0001574232)
Date: May 9, 2023 · CIK: 0001574232 · Accession: 0000000000-23-004854
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-271611
Letter
United States securities and exchange commission logo May 9, 2023 Tim Dyer Chief Executive Officer Addex Therapeutics Ltd. Chemin des Mines 9, CH-1202 Geneva, Switzerland Re:Addex Therapeutics Ltd. Registration Statement on Form F-1 Filed May 3, 2023 File No. 333-271611 Dear Tim Dyer: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Joshua A. Kaufman
Show Raw Text
United States securities and exchange commission logo
May 9, 2023
Tim Dyer
Chief Executive Officer
Addex Therapeutics Ltd.
Chemin des Mines 9,
CH-1202 Geneva,
Switzerland
Re:Addex Therapeutics Ltd.
Registration Statement on Form F-1
Filed May 3, 2023
File No. 333-271611
Dear Tim Dyer:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Joshua A. Kaufman